Anti-PD-L1 and PD-L2 antibody and derivatives and use thereof
AssigneeBiotheus Inc.
InventorsXiaoniu Miao, Fan Wu, Cheng Chen
Life of this patent
Estimating the term…
Abstract
A PD-L1 nano-antibody and a PD-L2 nano-antibody, and a bispecific antibody having both the PD-L1 nano-antibody and the PD-L2 nano-antibody are disclosed. The bispecific antibody can block PD-1/PD-L1 and PD-1/PD-L2 pathways at the same time. The bispecific antibody can reactivate T cells, enhance immune responses, and more effectively improve the inhibitory effect on tumor occurrence and development.
Claims13
An anti-PD-L2 VHH single domain antibody, wherein the complementarity determining regions (CDRs) of the VHH chain of the anti-PD-L2 VHH single domain antibody are composed of the following:
- CDR1 with amino acid sequence as shown in SEQ ID NO:
- 57;
- CDR2 with amino acid sequence as shown in SEQ ID NO:
- 58;
- and CDR3 with amino acid sequence as shown in SEQ ID NO:
- 59;
- or
- CDR1 with amino acid sequence as shown in SEQ ID NO:
- 60;
- CDR2 with amino acid sequence as shown in SEQ ID NO:
- 61;
- and CDR3 with amino acid sequence as shown in SEQ ID NO:
- 62;
- or, the amino acid sequence of the VHH chain of the anti-PD-L2 VHH single domain antibody is as shown in SEQ ID NO:
- 1, 2, 4, 5, 6, 7, 8, 9, 10, 11, 13, 14, 17 or 18.
An anti-PD-L1 VHH single domain antibody, wherein the complementarity determining regions CDRs of the VHH chain of the anti-PD-L1 VHH single domain antibody are composed of the following:
- CDR1 with amino acid sequence as shown in SEQ ID NO:
- 63;
- CDR2 with amino acid sequence as shown in SEQ ID NO:
- 64;
- and CDR3 with amino acid sequence as shown in SEQ ID NO:
- 65.
Dependencies are inferred from the claim text.